key: cord-0936668-lfwurxu7
authors: Konuma, Takahiro; Ogawa, Kotaro; Okada, Yukinori
title: Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates
date: 2021-02-13
journal: Hum Mol Genet
DOI: 10.1093/hmg/ddab049
sha: 35001544454225ef749fa908e3773ea08f213b3c
doc_id: 936668
cord_uid: lfwurxu7

Approaches toward new therapeutics using disease genomics such as genome-wide association study (GWAS) are anticipated. Here we developed Trans-Phar (integration of Transcriptome-wide association study [TWAS] and pharmacological database), achieving in silico screening of compounds from a large-scale pharmacological database (L1000 Connectivity Map) that have inverse expression profiles compared to tissue-specific genetically regulated gene expression. After confirmation of the statistical robustness by the application of the null GWAS data and of enrichment in true-positive drug-disease relationships by the application of UK-Biobank GWAS summary statistics in broad disease categories, we applied GWAS summary statistics of large-scale European meta-analysis (17 traits; n(average) = 201 849) and the hospitalized COVID-19 (n = 900 687), which has urgent need for drug development. We detected potential therapeutic compounds, as well as anisomycin in schizophrenia (FDR-q = 0.056) and verapamil in hospitalized COVID-19 (FDR-q = 0.068) as top-associated compounds. This approach could be effective in disease genomics-driven drug development.

Genome-wide association studies (GWASs) have identified thousands of genomic loci associated with human complex traits (1) . Associations identified by GWASs would reveal the mechanism of disease susceptibility and novel clinical approaches, such as the identification of novel therapeutic targets and drug repositioning. Recent studies have shown that the success probability of a project whose drug target was supported by human genome information is about twice as high as that of a project without its support (2, 3) ; therefore, the utilization of human genetics in driving drug development is anticipated. Genetics-led approaches for new therapeutics have been performed in recent years (4) (5) (6) .

Despite the success of GWASs, the biological functions of the majority of the identified genomic loci are elusive. Nearly 90% of the GWAS loci are lying in noncoding regions (7) , which are enriched in tissue-or cell-type-specific transcriptional regulatory regions involved in disease susceptibility (8) . These results suggest that causal variants influence disease susceptibility by altering cell-type-specific regulatory elements, which result in altering gene regulation mechanisms, such as gene expression profiles. Recently, statistical methods to integrate GWAS results with the functional genomics data, such as quantitative trait loci (eQTL) data (9) , have been developed.

Transcriptome-wide association study (TWAS) is a method that integrates GWAS loci and eQTL data, such as the Genotype-Tissue Expression (GTEx) project data (10) , and statistically predicts trait-gene expression relationships called genetically regulated gene expression (GREx) (11, 12) .

TWAS has identified novel candidate genes significantly associated with disease susceptibility in a cell-type-specific way and yielded functional insights into disease susceptibility (13, 14) , but few of these insights have been directly utilized for pharmacological applications, such as drug discovery.

Recent reports have shown that expression signatures of human diseases, such as differentially expressed genes (DEGs) by comparing disease samples and normal tissue samples, were applied to identify compounds whose perturbations were correlated on the transcriptomic level (15) . The Connectivity Map (CMap) L1000 library is a public database in pharmacology, which contains large transcriptomic profiles of the dozens of cultivated cell lines treated with tens of thousands of bioactive compounds and has been utilized to compare to disease signature and to identify novel drugs or their mechanistic actions (16) . However, there exist few reports utilizing GREx as an expression signature to comprehensively detect compounds from large-scale databases.

In this study, we have hypothesized that compounds, which have inverse effects in gene expression profiles when compared to GREx from common diseases, could be detected as potential drug candidates effective for disease treatment. Here, we constructed the GWAS-TWAS-compound library integration pipeline software (Trans-Phar; integration of Transcriptome-wide association study and pharmacological database). This software conducts in silico screening of the compounds from the CMap L1000 library, which have an inverse correlation with GREx estimated from the inputted GWAS summary statistics. The features of our pipeline software are as follows: (1) Large-scale compound data source incorporated in our pipeline enables the detection of compounds on a broad scale. (2) Thirteen tissue or cell-type categories are incorporated, which are assigned based on the 29 GTEx tissues used as eQTL data in TWAS and 77 cell types from the CMap L1000 library database. This enables to detect compounds that affect tissue or cell-type category-specific manners. We applied Trans-Phar to the UK-Biobank GWAS summary statistics covering a broad range of human traits and diseases (17, 18) and to large-scale European GWAS meta-analysis summary statistics. Our results demonstrated that true-positive disease-drug relationships and potential novel drug or drug target candidates for inputted disease GWAS summary statistics were successfully detected.

We hypothesized that compounds, which have an inverse effect in gene expression profiles (i.e., negative correlation) when compared to GREx estimated from common disease GWAS, could be identified as potential drug candidates effective for disease treatment. Here, we constructed a GWAS-TWAS-compound library integration pipeline. The overview of our method is shown in Figure 1 . The method consists of the following three steps.

Step 1: We performed TWAS to predict GREx, which contained predicted up-regulated and down-regulated genes concerning each inputted GWAS summary statistics of the disease or trait. We chose the 44 tissues GTEx version 7 eQTL data for the TWAS analysis, whose sample sizes were >100. Then, we obtained top-ranked genes whose absolute values of the TWAS Z-scores were on the top 10%, which we defined as genes with drastically changed expression levels among GREx.

Step 2: We performed negative Spearman's rank correlation analysis for gene expression changes (Z-score) between top-ranked genes from GREx and LINCS CMap L1000 library data, which consist of 308,872 pairs of compound and compound-perturbed cell-type gene expression change data that belonged to 13 tissue-cell-type categories (Supplementary Figure 1) .

Step 3: We obtained output statistics as P-values from negative Spearman's rank correlation analysis. Each of which corresponds to a correlation P-value between top-ranked genes from the TWAS of a GTEx tissue and compound-perturbed gene expression change in a specific tissue or cell-type category. This pipeline (named Trans-Phar) was publicly available at GitHub (https://github.com/konumat/Trans-Phar). Our pipeline software requires the formatted GWAS summary statistics as input data and then outputs P-values and BH-adjusted FDR-q corresponding to each set of TWAS tissue-CMap L1000 library cell-type-compound (at a specific dose and at a specific time point).

To validate the robustness of our pipeline, we first applied negative controls (i.e., simulated null GWAS data) to the pipeline. The null GWAS data were created by performing GWAS and randomly assigning trait labels to a set of 381 genomes from the 1000 Genome Project (19) under normal distribution at 10 times. We performed negative spearman's rank correlation analysis using Next, to validate whether true-positive drug-disease relationships (which means the detection of the approved drug for the inputted disease itself) are statistically enriched in a broad range of human traits and diseases, we applied UK-Biobank GWAS summary statistics, which have contained a quite broad range of diseases and traits (17, 18) , to the pipeline. Using UK-Biobank GWAS summary statistics, we examined whether approved drugs for the disease of inputted GWAS were detected with statistical significance by the following method (Figure 2 ). We first collected the GWAS summary statistics (i) whose single nucleotide polymorphism (SNP)-based heritability calculated by linkage disequilibrium score regression (LDSC) (20, 21) were >0.001 and (ii) which had genome-wide significant variants (P < 5.0 × 10 −8 ). Of these, we further selected the 30 disease GWAS summary statistics in descending order of the number of the curated approved drugs from the ChEMBL database (22) and Therapeutic Target Database (TTD) (23). The selected 30 GWAS diseases consisted of six major disease categories (certain infectious and parasitic diseases, neoplasms, mental and behavioral disorders, diseases of the circulatory system, diseases of the respiratory system, and diseases of the musculoskeletal system and connective tissue;

Supplementary Table 1) .

We applied our Trans-Phar pipeline to these 30 GWAS summary statistics to obtain a total of 9,266,160 P-values from all cell-type-compound pairs (308,872 P-values per each inputted GWAS summary statistics) and a total of 102,348 P-values from all cell-type-approved drug pairs. Then, we visually assessed the distributions of these GWAS-TWAS-library linkage P-values (Figure 3a) . The Next, to evaluate the approved drug pairs from the viewpoint of tissue-cell-type specificity, we evaluated these approved drug pairs in each 13 tissue-cell-type category defined in Supplementary Figure 1 . The Q-Q plots of P-values which were separated into 13 tissue-cell-type categories showed more significant inflation than that of P-values from all cell-type-approved drug pairs, especially in skin category (Figure 3b ). In the skin category, 15 significantly associated disease and approved drug pairs (FDR-q < 0.1) were found (Supplementary Table 2 ). These pairs Considering these results, our pipeline could successfully detect already approved drugs with higher sensitivity in specific tissue-cell-type categories than all categories, from the inputted disease GWAS summary statistics.

Motivated by the empirical robustness and statistical power of our Trans-Phar pipeline, we then expanded the target GWAS from the UK-Biobank GWAS summary statistics into the large-scale

European GWAS meta-analysis summary statistics to further detect compounds that could be promising novel therapeutic targets. We collected a total of 17 large-scale European GWAS meta-analysis summary statistics, which consisted of three major categories (immune/allergy, metabolic/cardiovascular, and neuropsychiatric; Table 2 ). These GWAS had sufficient numbers of significant disease-related loci with relatively large estimates on SNP-based heritability calculated by LDSC (>0.01). We also adopted the latest COVID-19 GWAS meta-analysis results released by the COVID-19 Host Genetics Initiative (ANA_B2_V2 as hospitalized COVID vs. population, which was the largest-scale meta-analysis released from the consortium on July 2, 2020).

We applied our Trans-Phar pipeline to these GWAS meta-analysis summary statistics and obtained 308,872 P-values from all cell-type-compound pairs per each inputted GWAS summary statistics. As a result, we obtained sets of cell-type-compound pairs in a specific tissue-cell-type

category with reverse expression correlation. We highlighted the top 14 cell-type-compound pairs from seven diseases/traits in Table 3 (BH-adjusted FDR-q < 0.25). Further, 55 cell-type-compound pairs from nine diseases/traits are also shown in Supplementary Table 3 (BH-adjusted FDR-q < 0.50).

Especially, we found two strong GWAS-TWAS-compound linkages: (i) anisomycin relevance to the GREx at the brain (brain hypothalamus as GTEx tissue and NEU cell-type as CMap FDR-q = 0.068; Figure 4b ). In addition, the Q-Q plots of P-values which were separated into 13 tissue/cell-type categories showed more significant inflation than that of P-values from all cell-type-approved drug pairs especially in central nervous system category from schizophrenia ( Figure 4c ) and in hematopoietic tissue category from COVID-19 hospitalization (Figure 4d ). For schizophrenia, anisomycin (protein synthesis inhibitor), proscillaridin (Na+/K+-ATPase inhibitor) and digoxin (Na+/K+-ATPase inhibitor) were significantly detected (Supplemental Table 4 ). For COVID-19 hospitalization, verapamil (Ca2+ channel blocker), 7-nitroindazole (NOS inhibitor), orantinib (PDGFR inhibitor) and enzalutamide (androgen receptor inhibitor) were significantly detected (Supplemental Table 5 ). These results highlighted that disease-relevant tissue or cell-type categories were more likely to show apparent inflation than other tissue or cell-type categories.

As the top-ranked drug we found for schizophrenia, anisomycin was reported to protect cortical neurons from hypoxia-induced neuronal death in vitro (24) and to attenuate posttraumatic stress response in animal models (25 

10 independent groups (NCT no. NCT04351763). Although further functional and clinical assessments are warranted, our study suggested verapamil as one of the potential drug candidates for COVID-19.

Also, among the detected cell-type-compound pairs, we found compounds already approved for several diseases. For example, azacitidine, which we found relevant to GREx at adipose as GTEx tissue and adipose stem cells (ASCs) as CMap L1000 library from adult-onset asthma, is a DNA methyltransferase (DNMT) inhibitor and has been approved for myelodysplastic syndrome. ASCs are the mesenchymal stem cell (MSC) population found in adipose tissue and have been shown to down-regulate the production of various inflammatory mediators and to have the potential to be a treatment for asthma and allergic airway disease (27, 28, 29). The effects of azacitidine on ASCs were reported to reverse the age-related deterioration of adult MSCs (30). Therefore, azacitidine might be related to therapeutic intervention for asthma by ASCs. We also found several cardiac glycosides (proscillaridin, digoxin, and digitoxin) relevant to GREx at the central nervous system (brain hypothalamus/hippocampus as GTEx tissue and NPC cell-type as CMap L1000 library) from schizophrenia. Cardiac glycosides, which act on Na + ,K + pump as ion transport modulator, might be concordant with the results of GWAS performed so far for schizophrenia (31-33), whose schizophrenia-associated loci contain several ion channel-encoding genes. Ion transport modulation by Na + /K + -ATPase in neurons has been reported to affect depressive disorders through neuronal activity, neurotransmission, and so on (34) . In summary, in silico screening by our Trans-Phar pipeline successfully identified promising drug target candidates as well as the confirmation of approved drug and clinical indication linkages, with implications on cell-type-specific pathophysiology of the diseases.

The integration of a broad range of human phenotypes and large-scale compound databases should enhance in silico pharmacology for drug discovery and repositioning. In this study, our integration pipeline, named Trans-Phar, incorporated a functional genomics approach by TWAS from a broad range of diseases or traits and large-scale compound perturbation databases with gene expression levels. Our pipeline showed statistical robustness using simulated null GWAS data and demonstrated that it could detect both true-positive drug-disease relationships and potential drug candidates for inputted disease or trait GWAS summary statistics.

Our approach highlights several advantages. First, this approach is hypothesis-free, which is less dependent on any prior biological or chemical knowledge such as known drug-disease relationships. This feature should be effective especially when searching drug candidates for diseases with unknown etiology, such as the COVID-19 pandemic. Second, we expanded coverages of tissue and cell-type specificity evaluated through TWAS to comprehensively obtain GREx using eQTL data from 29 GTEx tissues. Also, we used a broad compound database of CMap L1000 library, which has been updated and extended in the last few years, containing transcriptomic profiles of dozens of cultivated cell lines treated with tens of thousands of compounds. These extensions enable a comprehensive approach to detect various bioactive compounds in a broad range of tissue-cell-type categories. Third, our approach was computationally simple and only requested publicly available data, such as GWAS summary statistics and compound-perturbed gene expression data. It is easy for users to refine the pipeline to include additional resources, such as in-house disease-related gene expression data and compound libraries. These advantages should accelerate finding novel drugs or therapeutic targets under different mechanisms for a broad range of diseases and a broad category of organs. Our approach would also be useful for the diseases with few known treatments or urgent need for drug development such as the COVID-19 pandemic.

There are a few limitations to our approach. First, the hypothesis of finding compounds In conclusion, we have developed a framework for detecting potential drug or drug target candidates for disease susceptibility. Our study demonstrated that the Trans-Phar pipeline could find novel drug-disease relationships in tissue-or cell-type-specific manners. Our framework would be useful for therapeutic approaches such as drug development and drug-repositioning to a broad range of complex diseases or traits.

TWAS was performed using the FOCUS software (35) for each of the GWAS summary statistics. The European 1000 Genomes version 3 LD panel was used for TWAS. We chose 44 GTEx version 7 eQTL data whose sample size was >100 as an eQTL expression panel for TWAS. We obtained the predicted gene expression level in each tissue. After conducting TWAS, the top-ranked genes (top decile in the absolute value of the TWAS Z-score) were used in the following correlation analyses.

We used LINCS CMap L1000 library data (phases I and II) as compound library data (16) .

Level 5 data (moderated Z-scores from each perturbagen treatment on each cell) were downloaded from the Gene Expression Omnibus database, whose accession numbers were GSE92742 and GSE70138, respectively. In these data, we chose compound-perturbed gene expression data, which consist of 83 cell types and 20,547 compounds. For each compound-perturbed gene expression data, we defined significant DEGs using gene expression change data (Z-score) with cutoff BH-adjusted FDR-q < 0.01 and then excluded data whose significant DEGs were lower than 5. Then, we defined 13 tissue-cell-type categories (adipose, breast, central nervous system, digestive, hematopoietic system, liver, lung, musculoskeletal system, ovary, pancreas, prostate, skin, and uterus) and assigned 29 GTEx tissues and 77 LINCS CMap L1000 library cell types to 13 categories (Supplementary Figure 1) . Then, we performed negative Spearman's rank correlation analysis of all the pairs of top-ranked genes derived from each tissue GREx and each compound-perturbed gene expression data within the same tissue-cell-type category. Finally, we obtained a total of 308,872 P-values corresponding to each of the correlation analyses as described above.

We developed this pipeline as publicly available software named Trans-Phar (in https://github.com/konumat/Trans-Phar). This pipeline software needs the formatted GWAS summary statistics as input data and then outputs P-values and BH-adjusted FDR-q corresponding to

14 each set of the TWAS tissue-CMap L1000 library cell-type-compound pairs (at a specific dose and at a specific time point).

To empirically evaluate the statistical robustness of our pipeline, we tested our pipeline using 10 simulated null GWAS data, as negative-control GWAS summary statistics, which were created as described below. We obtained a total of 10 patterns of cell-type-compound P-value distributions, each of which contained 308,872 P-values. We used the distribution of the median of each P-value, which was sorted in ascending order, as negative-control P-value distribution. We also visually compared negative-control P-value distribution to the null hypothesis using a Q-Q plot.

To validate whether true-positive drug-disease relationships (which means the detection of the already approved drugs for the treatment of the inputted diseases themselves) can be detected in a broad range of human traits and diseases, we applied 30 UK-Biobank GWAS summary statistics to our pipeline. The criteria for the selection of the 30 UK-Biobank GWAS summary statistics were as follows: (1) diseases with comparatively high SNP-based heritability in the GWAS and (2) diseases enriched with curated already approved drugs corresponding to each disease itself, as described later.

We assessed negative Spearman's rank correlation analysis of the pairs of the top-ranked genes derived from each tissue GREx and approved drug-perturbed gene expression data in addition to all the pairs of the top-ranked genes derived from each tissue's GREx and each compound-perturbed gene expression data. We evaluated these 30 GWAS summary statistics to obtain a total of 9,266,160 To validate specificity of tissue or cell-type categories in 102,348 P-values from all cell-type-approved drug pairs described above, we separated 102,348 P-values to 13 tissue or cell-type categories defined in Supplemental Figure 1 . Then we also compared the distribution of these P-values under the null hypothesis. BH-adjusted FDR-q values were calculated for the correction for multiple testing of correlation analysis within each tissue or cell-type categories.

To evaluate the integration pipeline to find potential drug candidates effective for inputted GWAS summary statistics, we chose 17 European GWAS meta-analysis summary statistics from three disease/trait categories, as described below. We obtained 308,872 P-values from all pairs of top-ranked genes derived from each tissue GREx and each compound-perturbed gene expression data per inputted GWAS summary statistics. We also obtained P-values of each 13 tissue or cell-type category by separating 308,872 P-values into these categories. Then, we calculated the BH-adjusted FDR-q for the correction for multiple testing of correlation analysis.

To evaluate true-positive drug-disease relationship enrichment in a broad range of human traits and diseases, we collected the UK-Biobank GWAS summary statistics from the GeneATLAS database (n Phenotype = 778) (18) . For the 778 GWAS summary statistics, we applied the following Table 1 ].

To detect potential drug candidates with enhanced statistical power, we then used the large-scale European GWAS meta-analysis summary statistics. We curated 17 European GWAS meta-analysis summary statistics, for which a large number of significant disease-related loci were reported and whose SNP-based heritability was >0.01. These 17 European GWAS meta-analysis summary statistics consist of three major categories [immune/allergy (n = 8), metabolic/cardiovascular (n = 5), and neuropsychiatric (n = 4)]. Also, we adopted the COVID-19 meta-analysis GWAS summary statistics, for which urgent drug-repositioning strategy has been needed. COVID-19 GWAS meta-analysis round 3 data (ANA_B2_V2 as hospitalized COVID vs.

population) were downloaded from the COVID-19 Host Genetics Initiative (July 2, 2020 release).

All the GWAS summary statistics used for the detection of potential drug candidates are shown in Table 2 .

As the negative-control input data for our pipeline, we created randomized dummy trait GWAS datasets by randomly assigning trait labels to a set of 381 European human genomes from the 1000 Genome Project (19) under the assumption of following a normal distribution (average = 100; standard deviation = 20). GWAS on the randomized trait data were performed using the linear

regression analysis method implemented in PLINK2 (36) . We performed GWAS using randomized trait data with repetition of trait randomization at 10 times and then obtained a total of 10 randomized trait GWAS summary statistics as negative controls.

We collected the compound information on current, or previously developed, clinical

indications from the ChEMBL database version 25 (22) and TTD version 6. 

All the data used for this analysis was obtained from the public databases as indicated in URLs.

Python/R/Shell scripts for the Trans-Phar pipeline are available at Trans-Phar GitHub repository (https://github.com/konumat/Trans-Phar). Step 1: TWAS is performed to predict GREx per GTEx tissue using GTEx version 7 eQTL data concerning the inputted GWAS summary disease or trait.

Step 2: Negative Spearman's rank correlation analyses are performed using the top 10% of GREx per tissue and LINCS CMap L1000 library data (cell-type and cell-perturbed compound pairs) for every tissue-cell-type category.

Step 3:

Compounds that inversely correlate with GREx from each tissue with statistical significance are outputted, and its correlation-detected tissues and cell types are also outputted. The therapeutic targets with FDR-q < 0.25 are listed.

Years of GWAS Discovery: Biology, Function, and Translation

The support of human genetic evidence for approved drug indications

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

Genetics of rheumatoid arthritis contributes to biology and drug discovery

GREP: genome for REPositioning drugs

A genetics-led approach defines the drug target landscape of 30 immune-related traits

Genetic and epigenetic fine mapping of causal autoimmune disease variants

An Expanded View of Complex Traits: From Polygenic to Omnigenic

From GWAS to Function: Using Functional Genomics to Identify the Mechanisms Underlying Complex Diseases

Genetic effects on gene expression across human tissues

Opportunities and challenges for transcriptome-wide association studies

Integrative approaches for large-scale transcriptome-wide association studies

Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights

Integrating Gene Expression with Summary Association Statistics to Identify Genes Associated with 30 Complex Traits

Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

The UK Biobank resource with deep phenotyping and genomic data

An atlas of genetic associations in UK Biobank

A global reference for human genetic variation

Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3

LD Score regression distinguishes confounding from polygenicity in genome-wide association studies

The ChEMBL database in 2017

Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection

Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes

Probabilistic fine-mapping of transcriptome-wide association studies

PLINK: rising to the challenge of larger and richer datasets. Gigascience, 4, 7. Reference PubMed ID Amyotrophic lateral sclerosis (ALS) Neuropsychiatric (20

Asthma (adult-onset)

Immune/allergy

Immune/allergy

Body mass index Metabolic/cardiovascular 344,069 25673413 Coronary artery disease Metabolic/cardiovascular (57

Celiac disease Immune/allergy

Crohn's disease Immune/allergy (12,194

Diastolic blood pressure Metabolic/cardiovascular 361,141 31427789 Type 2 diabetes mellitus Metabolic/cardiovascular (48

Systolic blood pressure (SBP) Metabolic/cardiovascular 361,402 31427789 Schizophrenia Neuropsychiatric (40

Systemic lupus erythematosus Immune/allergy

COVID-19

We acknowledge the members of the COVID-19 Host Genetics Initiative for kindly releasing the GWAS summary statistics. This study was supported by the Japan Society for the Promotion of 

The authors declare no competing interests.